On August 24, the Tucson Unified School District (TUSD) in Arizona announced a settlement with Altria, in which they will receive a settlement amount of $3.2 million. Previously, the district had reached a settlement of around $10 million with Juul, both being part of the same class action lawsuit.
Dr. Ravi Shah, President of TUSD, stated:
Our staff has devoted a substantial amount of time conducting research, gathering evidence, and analyzing various aspects, all of which demonstrate the impact of Juul and Altria, as well as their influence on our school district.
The school district will begin receiving this sum of money starting at the end of this year and will continue to receive the remaining settlement funds in the coming years. The district's attorneys will receive 25% of the compensation amount. After deducting this fee, the school district will be left with approximately $10.3 million from these two settlements.
Ravi hopes that every cent of this money will be used to aid in the prevention and treatment of addiction issues among our students, as well as to meet their mental health needs. He stated that the school district already has plans in place to assist students, but the additional funding will further support their efforts.
Previously, Altria Group announced that it will pay $235 million to settle at least 6,000 lawsuits.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
